Abstract
Generation of reactive oxygen species is one of the major contributors in arsenic-induced genotoxicity where reduced glutathione (GSH) could be an important determining factor. To understand the role of endogenous GSH, arsenic trioxide (As2O3) was administered in buthionine sulfoximine (BSO)- and N-acetyl-L-cysteine (NAC)-treated mice. As2O3-induced significant chromosome aberrations (CAs) in all treatment groups compared with the control. BSO-treated mouse bone marrow cells showed significant CAs at a dose of 2 mg As2O3 kg(-1) b.w. Similar induction was not evident at 4 mg As2O3 kg(-1) b.w. and exhibited antagonistic effect at 8 mg As2O3 kg(-1) b.w. To understand this differential effect, expression pattern of Nrf2 was observed. Nrf2 expression increased following As2O3 treatment in a dose-dependent manner up to 4 mg As2O3 kg(-1) b.w after which no further increase was noticed. NAC pre-treatment significantly reduced the extent of As2O3-induced CAs suggesting the protective role of endogenous GSH against arsenic-induced genotoxicity.
Keywords:
Arsenic trioxide; N-acetyl-l-cysteine; buthionine sulfoximine; genotoxicity; glutathione; mouse bone marrow cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcysteine / pharmacology
-
Adaptor Proteins, Signal Transducing / agonists
-
Adaptor Proteins, Signal Transducing / antagonists & inhibitors
-
Adaptor Proteins, Signal Transducing / genetics
-
Adaptor Proteins, Signal Transducing / metabolism*
-
Animals
-
Arsenic Trioxide
-
Arsenicals / administration & dosage
-
Arsenicals / antagonists & inhibitors
-
Bone Marrow Cells / drug effects*
-
Bone Marrow Cells / metabolism
-
Bone Marrow Cells / pathology
-
Buthionine Sulfoximine / pharmacology
-
Chromatids / drug effects
-
Chromatids / pathology
-
Chromosome Aberrations / chemically induced
-
Cytoskeletal Proteins / agonists
-
Cytoskeletal Proteins / antagonists & inhibitors
-
Cytoskeletal Proteins / genetics
-
Cytoskeletal Proteins / metabolism*
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / pharmacology
-
Free Radical Scavengers / pharmacology
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Glutamate-Cysteine Ligase / antagonists & inhibitors
-
Glutamate-Cysteine Ligase / metabolism
-
Glutathione / agonists
-
Glutathione / antagonists & inhibitors
-
Glutathione / metabolism
-
Kelch-Like ECH-Associated Protein 1
-
Male
-
Membrane Glycoproteins / agonists
-
Membrane Glycoproteins / antagonists & inhibitors
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / metabolism*
-
Mice
-
Mutagens / administration & dosage
-
Mutagens / chemistry
-
Mutagens / toxicity*
-
NF-E2-Related Factor 2 / agonists
-
NF-E2-Related Factor 2 / antagonists & inhibitors
-
NF-E2-Related Factor 2 / genetics
-
NF-E2-Related Factor 2 / metabolism*
-
Neoplasm Proteins / agonists
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism
-
Nuclear Pore Complex Proteins / agonists
-
Nuclear Pore Complex Proteins / antagonists & inhibitors
-
Nuclear Pore Complex Proteins / genetics
-
Nuclear Pore Complex Proteins / metabolism*
-
Oxides / administration & dosage
-
Oxides / antagonists & inhibitors
-
Oxides / toxicity*
Substances
-
Adaptor Proteins, Signal Transducing
-
Arsenicals
-
Cytoskeletal Proteins
-
Enzyme Inhibitors
-
Free Radical Scavengers
-
Keap1 protein, mouse
-
Kelch-Like ECH-Associated Protein 1
-
Membrane Glycoproteins
-
Mutagens
-
NF-E2-Related Factor 2
-
Neoplasm Proteins
-
Nfe2l2 protein, mouse
-
Nuclear Pore Complex Proteins
-
Oxides
-
nuclear pore protein p62
-
Buthionine Sulfoximine
-
Glutamate-Cysteine Ligase
-
Glutathione
-
Arsenic Trioxide
-
Acetylcysteine